Prospective Biopsy-Controlled Evaluation of Cell Death Biomarkers for Prediction of Liver Fibrosis and Nonalcoholic Steatohepatitis
Open Access
- 12 October 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 55 (2) , 455-464
Abstract
Fibrosis and steatosis are major histopathological alterations in chronic liver diseases. Despite various shortcomings, disease severity is generally determined by liver biopsy, emphasizing the need for simple noninvasive methods for assessing disease activity. Because hepatocyte cell death is considered a crucial pathogenic factor, we prospectively evaluated the utility of serum biomarkers of cell death to predict different stages of fibrosis and steatosis in 121 patients with chronic liver disease. We compared the M30 enzyme-linked immunosorbent assay (ELISA), which detects a caspase-cleaved cytokeratin-18 (CK-18) fragment and thereby apoptotic cell death, with the M65 ELISA, which detects both caspase-cleaved and uncleaved CK-18 and thereby overall cell death. Both biomarkers significantly discriminated patients with different fibrosis stages from healthy controls. However, whereas both markers differentiated low or moderate from advanced fibrosis, only the M65 antigen could discriminate even lower stages of fibrosis. The M65 assay also performed better in distinguishing low (≤10%) and higher (>10%) grades of steatosis. In a subgroup of patients, we evaluated the biomarkers for their power to predict nonalcoholic steatohepatitis (NASH). Importantly, both markers accurately differentiated healthy controls or simple steatosis from NASH. However, only serum levels of M65 antigen could differentiate simple steatosis from healthy controls. Conclusion: Cell death biomarkers are potentially useful to predict fibrosis, steatosis, or NASH. Compared with the widely used apoptosis marker M30, the M65 assay had a better diagnostic performance and even differentiated between lower fibrosis stages as well as between healthy individuals and patients with simple steatosis. (Hepatology 2012)Keywords
This publication has 48 references indexed in Scilit:
- Serum Markers of Hepatocyte Death and Apoptosis Are Non Invasive Biomarkers of Severe Fibrosis in Patients with Alcoholic Liver DiseasePLOS ONE, 2011
- Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancerEuropean Journal of Cancer, 2011
- Cell Death and FibrogenesisSeminars in Liver Disease, 2010
- Targeting Liver FibrosisHepatology, 2009
- Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic SteatohepatitisHepatology, 2009
- Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery PatientsClinical Gastroenterology and Hepatology, 2008
- Cellular and Molecular Mechanisms of Liver InjuryGastroenterology, 2008
- The NAFLD fibrosis scoreHepatology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated MouseThe Journal of Pharmacology and Experimental Therapeutics, 2004